Alcohol and drug use risks during pregnancy

Why substances matter biologically in pregnancy

The placenta is not a perfect filter. Alcohol, nicotine, cannabinoids, opioids, stimulants, and many sedatives can cross into the fetal circulation. Fetal metabolism is immature, so substances and their metabolites may persist longer than they would in an adult. At the same time, the embryo and fetus are undergoing rapid cell division, organ formation, brain development, placental vascular remodeling, and growth, all of which can be vulnerable to toxic exposures.

Timing matters, but there is no completely risk-free window. Early pregnancy is a critical period for organogenesis, when some exposures may increase the risk of congenital anomalies or pregnancy loss. Later pregnancy is a period of rapid brain growth and weight gain, when exposures may affect neurodevelopment, fetal growth, preterm birth risk, and newborn withdrawal or adaptation. Many people have overlapping exposures, such as alcohol plus nicotine or cannabis plus prescription sedatives, making individual risk difficult to predict.

Importantly, risk is not destiny. A single exposure does not automatically mean harm has occurred, and many pregnancies have good outcomes after early or limited exposure. The best next step is usually to stop further exposure if safe to do so, avoid self-detoxification when dependence is possible, and involve a prenatal clinician who can offer nonjudgmental assessment and follow-up.

Alcohol: no known safe amount

Alcohol is a well-established teratogen, meaning it can disrupt fetal development. Public health agencies advise that there is no known safe amount of alcohol use during pregnancy, no known safe type of alcohol, and no known safe time to drink. Beer, wine, liquor, cocktails, and binge drinking all contain ethanol, the substance responsible for fetal toxicity.

Alcohol exposure can contribute to fetal alcohol spectrum disorders, a group of lifelong conditions that may include characteristic facial features, growth deficiency, structural brain differences, learning disabilities, executive function problems, attention difficulties, behavioral dysregulation, and problems with social functioning. Alcohol use in pregnancy has also been associated with miscarriage, stillbirth, preterm birth, low birth weight, and congenital anomalies.

Binge drinking is particularly concerning because high peak blood alcohol concentrations can produce greater fetal exposure. However, lower or intermittent intake cannot be assumed safe. If you drank before recognizing pregnancy, try not to panic. Stop drinking now and tell your obstetric clinician or midwife what happened, including approximate timing and amount. They can help assess whether additional fetal evaluation, nutrition support, behavioral health referral, or substance use treatment would be useful.

Cannabis, vaping, and tobacco often overlap

Cannabis is sometimes perceived as natural or lower risk, and some pregnant people use it for nausea, sleep, anxiety, or appetite. However, major health organizations discourage marijuana use in pregnancy. Tetrahydrocannabinol, or THC, crosses the placenta, and prenatal cannabis exposure has been linked in research with lower birth weight, possible effects on attention and neurodevelopment, and increased risk when combined with tobacco or other substances.

Smoking cannabis also introduces combustion products similar to those found in smoke exposure, and vaping products may contain nicotine, THC concentrates, solvents, flavoring chemicals, or contaminants. Product potency is variable, and labels may not reliably reflect fetal exposure. Edibles can lead to delayed but prolonged intoxication, increasing the risk of accidental high-dose exposure.

Tobacco and nicotine deserve specific mention because they commonly co-occur with alcohol or drug use. Nicotine exposure is associated with placental problems, fetal growth restriction, preterm birth, low birth weight, and sudden infant death syndrome risk. If nicotine is part of the picture, ask about evidence-based cessation options and behavioral support. For more detailed counseling, an internal resource on smoking and secondhand smoke risks during pregnancy may be relevant.

Opioids and neonatal abstinence syndrome

Opioid exposure in pregnancy may involve prescribed pain medicines, nonmedical use of prescription opioids, heroin, or synthetic opioids such as fentanyl. Risks can include poor fetal growth, placental complications, preterm birth, stillbirth, and neonatal abstinence syndrome, also called neonatal opioid withdrawal syndrome. Newborns with withdrawal may have tremors, irritability, high-pitched crying, feeding difficulty, vomiting, diarrhea, temperature instability, poor sleep, and sometimes seizures, depending on exposure patterns and co-exposures.

For opioid use disorder, abrupt withdrawal without medical supervision is generally not recommended because it can increase maternal distress, relapse risk, overdose risk, and unstable fetal exposure. Evidence-based treatment during pregnancy often includes medication for opioid use disorder, such as methadone or buprenorphine, combined with prenatal care, behavioral health support, infectious disease screening, and social services. The exact treatment plan must be individualized by clinicians experienced in pregnancy and addiction medicine.

People taking prescribed opioids for pain should not stop or change the dose on their own. Instead, they should review the indication, dose, duration, alternatives, and fetal/newborn considerations with their prescriber and prenatal clinician. The goal is to balance maternal function and safety with fetal risk reduction.

Stimulants: cocaine, methamphetamine, and related risks

Stimulants such as cocaine and methamphetamine can affect pregnancy through vasoconstriction, hypertension, appetite suppression, sleep disruption, and effects on placental blood flow. Cocaine has been associated with serious maternal complications, including hypertensive crises, arrhythmias, seizures, myocardial ischemia, and placental abruption, a dangerous premature separation of the placenta from the uterine wall. Fetal risks may include growth restriction, preterm birth, stillbirth, and neurobehavioral effects.

Methamphetamine use has been associated with low birth weight, small size for gestational age, preterm birth, and maternal complications related to cardiovascular strain, malnutrition, infections, and mental health instability. Stimulant use can also increase exposure to unsafe environments, sleep deprivation, intimate partner violence, and inconsistent prenatal care, all of which compound risk.

If stimulant use is ongoing, medical care should focus on safety, cardiovascular and obstetric assessment, mental health support, and connection to substance use treatment. Emergency care is needed for chest pain, severe headache, seizures, severe abdominal pain, heavy bleeding, fainting, or decreased fetal movement later in pregnancy.

Sedatives, benzodiazepines, and polysubstance exposure

Benzodiazepines, barbiturates, sleep medications, and other sedating substances may be prescribed, misused, or combined with opioids or alcohol. This combination is especially concerning because it can suppress breathing, increase overdose risk, impair judgment, and contribute to falls or trauma. In newborns, some sedative exposures can contribute to poor tone, respiratory depression, feeding difficulty, or withdrawal-like symptoms.

People who have been taking benzodiazepines or heavy alcohol regularly should not abruptly stop without medical guidance, because withdrawal can be severe and may include seizures, delirium, autonomic instability, or relapse. A clinician can help weigh the risks of continued exposure against the risks of withdrawal and can coordinate a safer taper or treatment plan when appropriate.

Polysubstance use is common and often reflects attempts to manage withdrawal, pain, insomnia, anxiety, or trauma. Clinically, it matters because substances can interact. Alcohol plus opioids, opioids plus benzodiazepines, or stimulants plus sedatives may create unpredictable maternal and fetal effects. Honest disclosure allows the care team to prepare for newborn monitoring and reduce emergency risks.

What to do if exposure happened or use is ongoing

The most protective step is to involve healthcare professionals early. Many people avoid care because they fear judgment, legal consequences, or losing custody. These fears are real in some settings, but delayed care can increase risk. Ask for confidential, trauma-informed, culturally respectful support. If you feel dismissed or shamed, it is reasonable to request another clinician, addiction medicine referral, or social work support.

Practical steps may include:

• Tell your prenatal clinician what substances were used, how often, how much, by what route, and when the last exposure occurred.
• Do not stop alcohol, benzodiazepines, or opioids abruptly if you may be physically dependent; ask for urgent medical guidance.
• Ask about screening for anemia, infections, sexually transmitted infections, hepatitis, HIV, nutrition deficiencies, depression, anxiety, and intimate partner violence when relevant.
• Discuss fetal monitoring, such as ultrasound assessment of growth and anatomy, based on exposure type and gestational age.
• Plan newborn care, including observation for withdrawal, feeding support, safe sleep counseling, and pediatric follow-up.

Supportive care can include behavioral therapies, peer recovery programs, medication treatment for opioid use disorder, mental health treatment, housing assistance, nutrition support, and domestic violence resources. Recovery rarely depends on willpower alone; it is a medical and social process that benefits from coordinated care.

Breastfeeding and the postpartum period

Substance-related questions do not end at delivery. Some substances enter breast milk, and newborns vary in vulnerability depending on prematurity, medical status, exposure history, and feeding patterns. Breastfeeding may be encouraged in some treated and stable situations, such as certain patients receiving prescribed methadone or buprenorphine with no ongoing illicit drug use, but it may be unsafe with active use of cocaine, methamphetamine, nonprescribed opioids, heavy alcohol, or sedating combinations. Decisions should be individualized with obstetric, pediatric, and addiction medicine input.

The postpartum period is also a high-risk time for relapse, overdose, depression, anxiety, trauma symptoms, sleep deprivation, and loss of support. If opioid use disorder is present, overdose prevention planning is critical, including naloxone access for the patient and household members when appropriate. A written postpartum plan can include medication continuity, mental health follow-up, pediatric appointments, lactation guidance, contraception planning, and emergency contacts.

Partners and family members can help by reducing access to substances at home, avoiding judgmental language, attending appointments if invited, learning infant safe sleep practices, and supporting rest, meals, transportation, and recovery appointments.